Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 result for tildrakizumab (ilumetri)

  1. Tildrakizumab for treating moderate to severe plaque psoriasis (TA575)

    Evidence-based recommendations on tildrakizumab (Ilumetri) for treating moderate to severe plaque psoriasis in adults.

    Technology appraisal guidance
    Published
    17 April 2019
    View recommendations

    Sections for TA575